1. Home
  2. ACAD vs MRCY Comparison

ACAD vs MRCY Comparison

Compare ACAD & MRCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • MRCY
  • Stock Information
  • Founded
  • ACAD 1993
  • MRCY 1981
  • Country
  • ACAD United States
  • MRCY United States
  • Employees
  • ACAD N/A
  • MRCY N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • MRCY
  • Sector
  • ACAD Health Care
  • MRCY
  • Exchange
  • ACAD Nasdaq
  • MRCY Nasdaq
  • Market Cap
  • ACAD 2.5B
  • MRCY 2.8B
  • IPO Year
  • ACAD 2004
  • MRCY 1998
  • Fundamental
  • Price
  • ACAD $21.57
  • MRCY $49.25
  • Analyst Decision
  • ACAD Buy
  • MRCY Hold
  • Analyst Count
  • ACAD 14
  • MRCY 7
  • Target Price
  • ACAD $27.08
  • MRCY $46.71
  • AVG Volume (30 Days)
  • ACAD 3.0M
  • MRCY 537.3K
  • Earning Date
  • ACAD 05-07-2025
  • MRCY 05-06-2025
  • Dividend Yield
  • ACAD N/A
  • MRCY N/A
  • EPS Growth
  • ACAD N/A
  • MRCY N/A
  • EPS
  • ACAD 1.37
  • MRCY N/A
  • Revenue
  • ACAD $996,283,000.00
  • MRCY $887,477,000.00
  • Revenue This Year
  • ACAD $13.49
  • MRCY $7.83
  • Revenue Next Year
  • ACAD $10.58
  • MRCY $6.15
  • P/E Ratio
  • ACAD $15.76
  • MRCY N/A
  • Revenue Growth
  • ACAD 22.42
  • MRCY 5.66
  • 52 Week Low
  • ACAD $13.40
  • MRCY $26.48
  • 52 Week High
  • ACAD $25.23
  • MRCY $52.25
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 68.70
  • MRCY 58.19
  • Support Level
  • ACAD $21.95
  • MRCY $45.88
  • Resistance Level
  • ACAD $22.62
  • MRCY $49.54
  • Average True Range (ATR)
  • ACAD 1.21
  • MRCY 1.68
  • MACD
  • ACAD 0.23
  • MRCY 0.16
  • Stochastic Oscillator
  • ACAD 56.27
  • MRCY 94.76

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

Share on Social Networks: